Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Aug
31
Today In Oncology
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo